Gray James M, Maewal Jaya D, Lunos Scott A, Furnival Ronald A, Hendrickson Marissa A
From the Department of Pediatrics, University of Minnesota, Minneapolis, MN.
Department of Pediatrics, University of California, Davis, Sacramento, CA.
Pediatr Emerg Care. 2020 Mar;36(3):e120-e124. doi: 10.1097/PEC.0000000000001343.
Ondansetron has been shown to decrease admission rate and the need for intravenous fluids among pediatric emergency department (ED) patients with acute gastroenteritis, but there is limited evidence regarding its use after ED discharge. This study describes prescribing patterns for ondansetron and assesses the effects of ondansetron home prescription on rate of return.
Data were gathered from the electronic health record on 2 separate but overlapping groups of patients seen in a pediatric ED from 2012 to 2014. The Gastroenteritis Group included all patients with a discharge diagnosis of gastroenteritis by International Classification of Diseases, Ninth Revision, code. The All Ondansetron Group included any child prescribed ondansetron at discharge. Patterns of ondansetron use and 3- and 7-day ED return rate were assessed for both groups. Discharge diagnosis was evaluated for the All Ondansetron Group.
A total of 996 patients with acute gastroenteritis were identified during the study period. Of these, 76% received ondansetron in the ED, and 71% were discharged with prescriptions for ondansetron. Seven-day ED return rates were similar between groups (6% with prescription, 5% without, P = 0.66). A total of 2287 patients received home prescriptions for ondansetron. Fifty-four percent of these patients' discharge diagnoses were classed as gastrointestinal complaints, 14% other infectious conditions, 9% respiratory, and 4% injuries. Their return rate was 6%. There was wide variation in the number of doses prescribed.
Home-use ondansetron is widely prescribed in this urban academic pediatric ED for a variety of indications, without effect on 3- or 7-day ED return. Further prospective studies are necessary to determine the efficacy of this practice.
已证实昂丹司琼可降低急性胃肠炎儿科急诊科(ED)患者的住院率及静脉补液需求,但关于其在ED出院后的使用证据有限。本研究描述了昂丹司琼的处方模式,并评估了昂丹司琼家庭处方对复诊率的影响。
从电子健康记录中收集了2012年至2014年在一家儿科ED就诊的2个独立但有重叠的患者组的数据。胃肠炎组包括所有出院诊断为根据国际疾病分类第九版编码的胃肠炎的患者。所有昂丹司琼组包括任何出院时开具昂丹司琼处方的儿童。评估了两组昂丹司琼的使用模式以及3天和7天的ED复诊率。对所有昂丹司琼组的出院诊断进行了评估。
在研究期间共确定了996例急性胃肠炎患者。其中,76%在ED接受了昂丹司琼治疗,71%出院时开具了昂丹司琼处方。两组的7天ED复诊率相似(有处方者为6%,无处方者为5%,P = 0.66)。共有2287例患者接受了昂丹司琼家庭处方。这些患者中54%的出院诊断归类为胃肠道疾病,14%为其他感染性疾病,9%为呼吸道疾病,4%为损伤。他们的复诊率为6%。所开剂量差异很大。
在这家城市学术性儿科ED中,昂丹司琼被广泛用于多种适应症的家庭用药,对3天或7天的ED复诊无影响。需要进一步的前瞻性研究来确定这种做法的疗效。